Novo Nordisk's New Weight-Loss Pill Shows Promising Results
TL;DR Summary
Novo Nordisk's new amylin-based obesity drug, amycretin, shows significant weight loss in early trials, but similar efficacy across different doses and high side effects raise questions about optimal dosing strategies.
- Full data on Novo Nordisk’s new amylin drug raise dosing questions STAT
- Novo Nordisk's experimental drug results in up to 24% weight loss Reuters
- Weight loss pill set to rival injections after promising studies The Independent
- Novo’s Latest Obesity Drug Shows 24% Weight Loss in Small Trial Bloomberg
- New weight-loss drug is ‘better than Wegovy’ — and comes in a pill The Times
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
86%
207 → 30 words
Want the full story? Read the original article
Read on STAT